Novo Nordisk opens Wogovy to Telesalud in impulse for new patients

Novo Nordisk Tuesday said he will offer his weight loss medication. Crazy Through telesalud suppliers Hims and his health, Ro and LIFEMD to expand access to the box office success treatment now that it is no longer scarce in the US.

The Hims & Hers shares rose to 30% in the negotiation prior to Tuesday, while Novo Nordisk’s shares increased 3%.

The Danish drug manufacturer is running to capture more patients now than many composite pharmacies are legally restricted from making cheaper and not approved versions of CrazyWith rare exceptions. The patients mass went to those compound versions, while Wagovy was scarcity due to the demand triggered.

“We feel it was really important to work hard to establish a collaboration with Telesalud companies so that there could be access to Wogovy, since the compound is decreasing,” Dave Moore, executive vice president of US operations in Novo Nordisk, told CNBC.

“We are really happy with the level of interest to access WOGOVY branded and start catching people as they leave compound medicine,” he said.

Moore added that the new associations make the experience “perfect” for patients, since it allows them to access the grill directly from their telesalud suppliers, which “makes it very easy for them to send the medication directly to their homes.

Patients will be able to access the new direct online pharmacy to the Novo Nordisk consumer, Novocariadirectly through Telesalud Suppliers

That pharmacy offers Wagovy for $ 499 in cash, approximately half of its usual monthly list price, for patients without insurance coverage for weekly injection.

The price of each Telesalud company may be higher because they probably include additional services, said a spokesman for Novo Nordisk to CNBC.

Hims & Hers said that it will begin offering all the dose sizes of cursed along with access to 24/7 care, nutritional orientation and continuous clinical support this week, from $ 599 per month to eligible patients to pay cash with a recipe.

The medicine will cost its customers more to its customers, since it comes with additional access to attention, said the company’s CEO, Andrew Dudum, CNBC in an interview. He said he believes that the company’s association with Novo Nordisk will serve as a case study on how patients get access and will obtain prices of “great medicine” and other forms of treatment.

Ro opted for the lowest price, announcing on Tuesday that will offer access to all Wegovy doses for $ 499 per month. The company provides 24/7 messages, individual coaching, educational content and more through its monthly membership called Body program, which does not include the cost of medicines.

“Add the treatments approved by the FDA of Novo Nordisk to the best cash price will help more patients throughout the country to obtain the obesity care they need to achieve their objectives, particularly those without insurance coverage,” said the CEO of Ro, Zach Reitano, in a statement.

Earlier this month, Hims and hers announced that patients could access Eli LillyPEOPLE MEDICINE Zero and diabetes drug Mounjaroas well as the generic injection liraglutide, through its platform. But unlike the company’s collaboration with Novo Nordisk, Lilly He issued a statement that clarifies that he has no “affiliation” with hym and hers.

HIMS & HERS began to prescribe compound semaglutida, the active ingredient in Novo NordiskThe Ozempic and Wogovy diabetes medicine in May 2024. The company has had to stop offering mass compound medications, but some consumers can still access custom doses if it is clinically applicable, Dudum said.

“That was one of the first things we share with Novo is that we will always fight in the name of what consumers believe they have the right to obtain,” Dudum said. “The regulation is very clear.”

During Food and Decorated Medicines Administration ShortagePharmacists can legally make compound versions of brand medications. Case may also occur when medically necessary for a patient, such as when a pill cannot be swallowed or are allergic to a specific ingredient in a brand medication.

But drug manufacturers and some health experts have rejected the practice, in large part because the FDA does not approve composite drugs.

The largest composite pharmacies and regulated by the federal government that make copies of bulk semagglutidate without recipes face a legal deadline of May 22 to stop marketing and sell those versions. The smallest and graduate composite pharmacies in the state that manufacture semaglutidal imitators for individual recipes had a deadline of April 22.

“The spirit of this is that we stay faithful to what the rules are,” said Moore. “That is the best way to serve patients.”

– Brandon Gómez and Angelica Peebles de CNBC contributed to this report.